The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions
Abstract
The tumor microenvironment (TME) is a complex system composed of multiple cells, such as non-cancerous fibroblasts, adipocytes, immune and vascular cells, as well as signal molecules and mediators. Tumor cells recruit and reprogram other cells to produce factors that maintain tumor growth. Communication between cancerous and surrounding cells is a two-way process and engages a diverse range of mechanisms that, in consequence, can lead to rapid proliferation, metastasis, and drug resistance, or can serve as a tumors-suppressor, e.g., through tumor–immune cell interaction. Cross-talk within the cancer microenvironment can be direct by cell-to-cell contact via adhesion molecules, electrical coupling, and passage through gap junctions, or indirect through classical paracrine signaling by cytokines, growth factors, and extracellular vesicles. Therapeutic approaches for modulation of cell-cell communication may be a promising strategy to combat tumors. In particular, integrative approaches targeting tumor communication in combination with conventional chemotherapy seem reasonable. Currently, special attention is paid to suppressing the formation of open-ended channels as well as blocking exosome production or ablating their cargos. However, many aspects of cell-to-cell communication have yet to be clarified, and, in particular, more work is needed in regard to mechanisms of bidirectional signal transfer. Finally, it seems that some interactions in TEM can be not only cancer-specific, but also patient-specific, and their recognition would help to predict patient response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lung cancer progression partially results from the communications of tumor cells with host microenvironment. Such communications occur through the release of cytokines, chemokines and growth factors from cancer cells 37.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 6×
“Their expression not only changes in cancer cells but also in non-cancerous cells of TME [36].”
BackgroundInfluentialNaba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940 · cited 1×
“5) can impact surrounding cells and repress their antitumor activity [12].”
BackgroundTumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
Zhao, H., Yang, L., Baddour, J., Achreja, A., Bernard, V., Moss, T., Marini, J. C., Tudawe, T., Seviour, E. G., San Lucas, F. A., et al. (2016) · eLife · doi:10.7554/elife.10250 · Cited by 927 · cited 2×
“Among them, there are acetate, lactate, and TCA cycle metabolites: citrate, pyruvate and fumarate [83,121].”
BackgroundA draft network of ligand–receptor-mediated multicellular signalling in human
Ramilowski, J. A., Goldberg, T., Harshbarger, J., Kloppmann, E., Lizio, M., Satagopam, V. P., Itoh, M., Kawaji, H., Carninci, P., Rost, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8866 · Cited by 887
Crosstalk of tight junction components with signaling pathways
González-Mariscal, L., Tapia, R., & Chamorro, D. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.08.018 · Cited by 759 · cited 1×
“These connections mediate ion or other molecules transport and osmosis as well as dictate cell polarity [37,38].”
BackgroundTumor-associated stromal cells as key contributors to the tumor microenvironment
Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., & Marini, F. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0740-2 · Cited by 746
Exosomes are natural carriers of exogenous siRNA to human cells in vitro
Shtam, T. A., Kovalev, R. A., Varfolomeeva, E. Y., Makarov, E. M., Kil, Y. V., & Filatov, M. V. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-88 · Cited by 499
Research works printed but not linked: 174
- Bode, 2009, Cancer prevention research—Then and now, Nat. Rev. Cancer, 9, 508, 10.1038/nrc2646 · DOI · Paper page
- Helsper, 2017, Time to diagnosis and treatment for cancer patients in the Netherlands: Room for improvement?, Eur. J. Cancer, 87, 113, 10.1016/j.ejca.2017.10.003 · doi:10.1016/j.ejca.2017.10.003
- Schirrmacher, 2019, From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review), Int. J. Oncol., 54, 407, 10.3892/ijo.2018.4661 · DOI · Paper page
- Bergfeld, 2010, Bone marrow-derived mesenchymal stem cells and the tumor microenvironment, Cancer Metastasis Rev., 29, 249, 10.1007/s10555-010-9222-7 · DOI · Paper page
- Walker, C., Mojares, E., and Del Rio Hernandez, A. (2018). Role of Extracellular Matrix in Development and Cancer Progression. Int. J. Mol. Sci., 19. · DOI · Paper page
- Taube, 2018, Implications of the tumor immune microenvironment for staging and therapeutics, Modem Pathol., 31, 214, 10.1038/modpathol.2017.156 · DOI · Paper page
- Pasquier, 2013, Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance, J. Transl. Med., 11, 94, 10.1186/1479-5876-11-94 · DOI · Paper page
- Polak, 2015, B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment, Blood, 126, 2404, 10.1182/blood-2015-03-634238 · DOI · Paper page
- Petrova, 2018, The hypoxic tumour microenvironment, Oncogenesis, 7, 10, 10.1038/s41389-017-0011-9 · DOI · Paper page
- Albrengues, 2015, Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts, Nat. Commun., 6, 10204, 10.1038/ncomms10204 · DOI · Paper page
- Albrengues, 2014, LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep., 7, 1664, 10.1016/j.celrep.2014.04.036 · DOI · Paper page
- Scharenberg, 2014, TGF-β-induced differentiation into myofibroblasts involves specific regulation of two MKL1 isoforms, J. Cell Sci., 127, 1079
- Aasen, 2019, Connexins in cancer: Bridging the gap to the clinic, Oncogene, 38, 4429, 10.1038/s41388-019-0741-6 · DOI · Paper page
- Qu, 2002, Function of the voltage gate of gap junction channels: Selective exclusion of molecules, Proc. Natl. Acad. Sci. USA, 99, 697, 10.1073/pnas.022324499 · DOI
- Beckmann, A., Hainz, N., Tschernig, T., and Meier, C. (2019). Facets of Communication: Gap Junction Ultrastructure and Function in Cancer Stem Cells and Tumor Cells. Cancers (Basel), 11. · DOI
- Aasen, 2016, Gap junctions and cancer: Communicating for 50 years, Nat. Rev. Cancer, 16, 775, 10.1038/nrc.2016.105 · DOI · Paper page
- Loewenstein, 1966, Intercellular communication and the control of tissue growth: Lack of communication between cancer cells, Nature, 209, 1248, 10.1038/2091248a0 · DOI · Paper page
- Babica, 2016, Chemopreventive Agents Attenuate Rapid Inhibition of Gap Junctional Intercellular Communication Induced by Environmental Toxicants, Nutr. Cancer, 68, 827, 10.1080/01635581.2016.1180409 · DOI
- Xu, 2016, Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer, Oncotarget, 7, 67476, 10.18632/oncotarget.11231 · doi:10.18632/oncotarget.11231
- Yeh, 2017, Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration, Oncotarget, 8, 109358, 10.18632/oncotarget.22678 · DOI
- Arshad, 2018, Inhibition of Cx43 attenuates ERK1/2 activation, enhances the expression of Cav1 and suppresses cell proliferation, Int. J. Mol. Med., 42, 2811
- Sinyuk, 2018, Cancer Connectors: Connexins, Gap Junctions, and Communication, Front. Oncol., 8, 646, 10.3389/fonc.2018.00646 · DOI
- Kar, 2012, Biological role of connexin intercellular channels and hemichannels, Arch. Biochem. Biophys., 524, 2, 10.1016/j.abb.2012.03.008 · DOI · Paper page
- Sin, 2012, Opposing roles of connexin43 in glioma progression, Biochim. Biophys. Acta, 1818, 2058, 10.1016/j.bbamem.2011.10.022 · DOI
- Arora, S., Heyza, J.R., Chalfin, E.C., Ruch, R.J., and Patrick, S.M. (2018). Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling. Cancers (Basel), 10. · DOI
- Mattes, 2018, Emerging role of contact-mediated cell communication in tissue development and diseases, Histochem. Cell Biol., 150, 431, 10.1007/s00418-018-1732-3 · DOI
- Bosenberg, 1993, Juxtacrine cell signaling molecules, Curr. Opin. Cell Biol., 5, 832, 10.1016/0955-0674(93)90032-L · DOI
- Cuatrecasas, 1974, Membrane receptors, Annu. Rev. Biochem., 43, 169, 10.1146/annurev.bi.43.070174.001125 · DOI · Paper page
- Sever, R., and Brugge, J.S. (2015). Signal transduction in cancer. Cold Spring Harb. Perspect. Med., 5. · DOI · Paper page
- Ikenouchi, 2003, Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail, J. Cell Sci., 116, 1959, 10.1242/jcs.00389 · DOI · Paper page
- Martin, 2014, The role of tight junctions in cancer metastasis, Semin. Cell Dev. Biol., 36, 224, 10.1016/j.semcdb.2014.09.008 · DOI
- Ren, 1990, Ultrastructural differences in junctional intercellular communication between highly and weakly metastatic clones derived from rat mammary carcinoma, Cancer Res., 50, 358
- Takeichi, 2014, Dynamic contacts: Rearranging adherens junctions to drive epithelial remodelling, Nat. Rev. Mol. Cell Biol., 15, 397, 10.1038/nrm3802 · DOI · Paper page
- Ling, 2011, Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer, Int. J. Mol. Med., 27, 625, 10.3892/ijmm.2011.640 · DOI
- Mayer, 1993, E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration, Cancer Res., 53, 1690
- Zhai, 2008, Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas, World J. Gastroenterol., 14, 5665, 10.3748/wjg.14.5665 · doi:10.3748/wjg.14.5665
- Shiina, 2005, Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer, Cancer Res., 65, 2130, 10.1158/0008-5472.CAN-04-3398 · DOI
- Dusek, 2011, Desmosomes: New perpetrators in tumour suppression, Nat. Rev. Cancer, 11, 317, 10.1038/nrc3051 · DOI · Paper page
- Roehlecke, C., and Schmidt, M.H.H. (2020). Tunneling Nanotubes and Tumor Microtubes in Cancer. Cancers (Basel), 12. · DOI
- Drab, M., Stopar, D., Kralj-Iglic, V., and Iglic, A. (2019). Inception Mechanisms of Tunneling Nanotubes. Cells, 8. · DOI
- Morel, 2017, Role of connexin 43 in different forms of intercellular communication—Gap junctions, extracellular vesicles and tunnelling nanotubes, J. Cell Sci., 130, 3619, 10.1242/jcs.200667 · DOI · Paper page
- Desir, S., Wong, P., Turbyville, T., Shetty, M., Clark, C., Zhai, E., Romin, Y., Manova-Todorova, K., and Starr, T.K. (2019). Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells. Cancers (Basel), 11. · DOI
- Berruti, 2018, RalGPS2 is involved in tunneling nanotubes formation in 5637 bladder cancer cells, Exp. Cell Res., 362, 349, 10.1016/j.yexcr.2017.11.036 · DOI
- Asencio-Barria, C., Defamie, N., Saez, J.C., Mesnil, M., and Godoy, A.S. (2019). Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer. Cancers (Basel), 11. · DOI
- Pasquier, 2012, Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells, J. Biol. Chem., 287, 7374, 10.1074/jbc.M111.312157 · DOI
- Thayanithy, 2014, Tumor-stromal cross talk: Direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes, Transl. Res., 164, 359, 10.1016/j.trsl.2014.05.011 · DOI · Paper page
- Nawaz, 2017, Extracellular Vesicles, Tunneling Nanotubes, and Cellular Interplay: Synergies and Missing Links, Front. Mol. Biosci., 4, 50, 10.3389/fmolb.2017.00050 · DOI
- Murray, 2019, Concise Review: Intercellular Communication Via Organelle Transfer in the Biology and Therapeutic Applications of Stem Cells, Stem Cells, 37, 14, 10.1002/stem.2922 · DOI
- Wang, 2011, Tunneling-nanotube development in astrocytes depends on p53 activation, Cell Death Differ., 18, 732, 10.1038/cdd.2010.147 · DOI · Paper page
- Babenko, 2015, Improving the Post-Stroke Therapeutic Potency of Mesenchymal Multipotent Stromal Cells by Cocultivation with Cortical Neurons: The Role of Crosstalk Between Cells, Stem Cells Transl. Med., 4, 1011, 10.5966/sctm.2015-0010 · DOI
- Osswald, 2015, Brain tumour cells interconnect to a functional and resistant network, Nature, 528, 93, 10.1038/nature16071 · DOI · Paper page
- Osswald, 2016, A malignant cellular network in gliomas: Potential clinical implications, Neuro Oncol., 18, 479, 10.1093/neuonc/now014 · DOI
- Abounit, 2015, Identification and Characterization of Tunneling Nanotubes for Intercellular Trafficking, Curr. Protoc. Cell Biol., 67, 12.10.11, 10.1002/0471143030.cb1210s67 · DOI
- Okafo, 2017, Tunneling nanotubes (TNT) mediate long-range gap junctional communication: Implications for HIV cell to cell spread, Sci. Rep., 7, 16660, 10.1038/s41598-017-16600-1 · DOI
- Liu, 2019, Exosomes as critical mediators of cell-to-cell communication in cancer pathogenesis and their potential clinical application, Transl. Cancer Res., 8, 298, 10.21037/tcr.2019.01.03 · DOI
- Kanada, 2016, Signaling by Extracellular Vesicles Advances Cancer Hallmarks, Trends Cancer, 2, 84, 10.1016/j.trecan.2015.12.005 · DOI
- Lotvall, 2014, Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles, J. Extracell. Vesicles, 3, 26913, 10.3402/jev.v3.26913 · DOI · Paper page
- Sadallah, 2011, Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells, J. Immunol., 186, 6543, 10.4049/jimmunol.1002788 · DOI · Paper page
- Savina, 2005, Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner, Traffic, 6, 131, 10.1111/j.1600-0854.2004.00257.x · DOI · Paper page
- Oves, M., Qari, H., Felemban, N., Aslam, A., Khan, A.A., Rehan, M., Tabrez, S., Ahmed, F., Haque, A., and Khan, I. (2018). Exosomes: A Paradigm in Drug Development against Cancer and Infectious Diseases. J. Nanomater., 2018. · DOI
- Bujanda, 2016, Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer, Ann. Transl. Med., 4, 64
- Melo, 2014, Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis, Cancer Cell, 26, 707, 10.1016/j.ccell.2014.09.005 · DOI · Paper page
- Lv, 2012, Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro, J. Biol. Chem., 287, 15874, 10.1074/jbc.M112.340588 · DOI · Paper page
- Cheng, 2017, A comprehensive overview of exosomes in ovarian cancer: Emerging biomarkers and therapeutic strategies, J. Ovarian Res., 10, 73, 10.1186/s13048-017-0368-6 · DOI
- Blancas, 2018, The role of exosomes on colorectal cancer: A review, J. Gastroenterol. Hepatol., 33, 792, 10.1111/jgh.14049 · DOI
- Lowry, 2015, The Role of Exosomes in Breast Cancer, Clin. Chem., 61, 1457, 10.1373/clinchem.2015.240028 · DOI
- Tucci, 2018, Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity, Oncotarget, 9, 20826, 10.18632/oncotarget.24846 · DOI
- Pan, 2017, Exosomes in diagnosis and therapy of prostate cancer, Oncotarget, 8, 97693, 10.18632/oncotarget.18532 · DOI
- Corcoran, C., Rani, S., O’Brien, K., O’Neill, A., Prencipe, M., Sheikh, R., Webb, G., McDermott, R., Watson, W., and Crown, J. (2012). Docetaxel-resistance in prostate cancer: Evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE, 7. · DOI · Paper page
- Kong, 2015, Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells, Int. J. Cancer, 137, 1610, 10.1002/ijc.29542 · DOI
- Xiao, X., Yu, S., Li, S., Wu, J., Ma, R., Cao, H., Zhu, Y., and Feng, J. (2014). Exosomes: Decreased sensitivity of lung cancer A549 cells to cisplatin. PLoS ONE, 9. · DOI · Paper page
- Takahashi, 2014, Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer, FEBS Open Bio, 4, 458, 10.1016/j.fob.2014.04.007 · DOI · Paper page
- Li, 2005, Nanovesicular vaccines: Exosomes, Arch. Immunol. Ther. Exp. (Warsz), 53, 329
- Peinado, 2012, Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET, Nat. Med., 18, 883, 10.1038/nm.2753 · DOI · Paper page
- Whiteside, 2018, Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment, Semin. Immunol., 35, 69, 10.1016/j.smim.2017.12.003 · DOI · Paper page
- Peinado, 2017, Pre-metastatic niches: Organ-specific homes for metastases, Nat. Rev. Cancer, 17, 302, 10.1038/nrc.2017.6 · DOI · Paper page
- Liu, 2015, The exosomes in tumor immunity, Oncoimmunology, 4, e1027472, 10.1080/2162402X.2015.1027472 · DOI · Paper page
- Sethi, 2012, Multifaceted link between cancer and inflammation, Biosci. Rep., 32, 1, 10.1042/BSR20100136 · DOI · Paper page
- Amedei, 2013, The use of cytokines and chemokines in the cancer immunotherapy, Recent Pat. Anticancer Drug Discov., 8, 126, 10.2174/1574892811308020002 · DOI
- Li, 2009, Paradoxical roles of IL-4 in tumor immunity, Cell. Mol. Immunol., 6, 415, 10.1038/cmi.2009.53 · DOI
- Middleton, 2014, Interleukin-6: An angiogenic target in solid tumours, Crit. Rev. Oncol. Hematol., 89, 129, 10.1016/j.critrevonc.2013.08.004 · DOI
- 2006, The multifaceted roles of chemokines in malignancy, Cancer Metastasis Rev., 25, 357, 10.1007/s10555-006-9003-5 · DOI · Paper page
- Mannino, 2015, The paradoxical role of IL-10 in immunity and cancer, Cancer Lett., 367, 103, 10.1016/j.canlet.2015.07.009 · DOI · Paper page
- Salgado, 2003, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer, Int. J. Cancer, 103, 642, 10.1002/ijc.10833 · DOI · Paper page
- Lu, 2017, Impact of IL-12 in Cancer, Curr. Cancer Drug Targets, 17, 682, 10.2174/1568009617666170427102729 · DOI
- Setrerrahmane, 2017, Tumor-related interleukins: Old validated targets for new anti-cancer drug development, Mol. Cancer, 16, 153, 10.1186/s12943-017-0721-9 · DOI · Paper page
- Choudhry, 2018, Prospects of IL-2 in Cancer Immunotherapy, Biomed Res. Int., 2018, 9056173, 10.1155/2018/9056173 · DOI
- Martin, 2016, Targeting microenvironment in cancer therapeutics, Oncotarget, 7, 52575, 10.18632/oncotarget.9824 · DOI
- Hao, Y., Baker, D., and Ten Dijke, P. (2019). TGF-beta-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int. J. Mol. Sci., 20. · DOI · Paper page
- Liu, 2018, TGF-β signaling: A complex role in tumorigenesis (Review), Mol. Med. Rep., 17, 699
- Montfort, 2019, The TNF Paradox in Cancer Progression and Immunotherapy, Front. Immunol., 10, 1818, 10.3389/fimmu.2019.01818 · DOI · Paper page
- Ion, G.N.D., Nitulescu, G.M., and Popescu, C.I. (2019). Targeting TRAIL. Bioorg Med. Chem. Lett. · DOI
- Ikeda, 2002, The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev., 13, 95, 10.1016/S1359-6101(01)00038-7 · DOI · Paper page
- Chow, 2014, Chemokines in cancer, Cancer Immunol. Res., 2, 1125, 10.1158/2326-6066.CIR-14-0160 · DOI · Paper page
- Salcedo, 2000, Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression, Blood, 96, 34, 10.1182/blood.V96.1.34 · DOI · Paper page
- Payne, 2002, The role of chemokines in melanoma tumor growth and metastasis, J. Investig. Dermatol., 118, 915, 10.1046/j.1523-1747.2002.01725.x · DOI · Paper page
- Zheng, 2016, Recent advances in SCF ubiquitin ligase complex: Clinical implications, Biochim. Biophys. Acta, 1866, 12
- Carmeliet, 2005, VEGF as a key mediator of angiogenesis in cancer, Oncology, 69, 4, 10.1159/000088478 · DOI · Paper page
- Zeng, 2014, Epidermal growth factor, from gene organization to bedside, Semin. Cell Dev. Biol., 28, 2, 10.1016/j.semcdb.2014.01.011 · DOI · Paper page
- Jutten, 2014, EGFR signaling and autophagy dependence for growth, survival, and therapy resistance, Cell Cycle, 13, 42, 10.4161/cc.27518 · DOI
- Newell, 2017, Placental growth factor: What hematologists need to know, Blood Rev., 31, 57, 10.1016/j.blre.2016.08.004 · DOI
- Heldin, 2013, Targeting the PDGF signaling pathway in tumor treatment, Cell Commun. Signal., 11, 97, 10.1186/1478-811X-11-97 · DOI · Paper page
- Vella, V., Malaguarnera, R., Nicolosi, M.L., Morrione, A., and Belfiore, A. (2019). Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection. Biochim. Biophys. Acta Mol. Cell Res., 118522. · DOI
- Sarkar, 2016, Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets, Biomicrofluidics, 10, 054115, 10.1063/1.4964716 · doi:10.1063/1.4964716
- Yuan, 2019, Systematic expression analysis of ligand-receptor pairs reveals important cell-to-cell interactions inside glioma, Cell Commun. Signal., 17, 48, 10.1186/s12964-019-0363-1 · DOI
- Lucchetti, D., Ricciardi Tenore, C., Colella, F., and Sgambato, A. (2020). Extracellular Vesicles and Cancer: A Focus on Metabolism, Cytokines, and Immunity. Cancers (Basel), 12. · DOI
- Santi, 2015, Cancer associated fibroblasts transfer lipids and proteins to cancer cells through cargo vesicles supporting tumor growth, Biochim. Biophys. Acta, 1853, 3211, 10.1016/j.bbamcr.2015.09.013 · DOI
- Curtis, 2019, Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis, Cell Metab., 29, 141, 10.1016/j.cmet.2018.08.007 · DOI · Paper page
- Vasseur, 2016, Lipid metabolic reprogramming in cancer cells, Oncogenesis, 5, e189, 10.1038/oncsis.2015.49 · DOI · Paper page
- Shender, 2014, Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication, Mol. Cell. Proteom., 13, 3558, 10.1074/mcp.M114.041194 · DOI
- Nieman, 2011, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat. Med., 17, 1498, 10.1038/nm.2492 · DOI · Paper page
- Tang, 2016, Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC), Oncotarget, 7, 46253, 10.18632/oncotarget.10086 · DOI
- Wang, 2010, Eicosanoids and cancer, Nat. Rev. Cancer, 10, 181, 10.1038/nrc2809 · DOI · Paper page
- Chang, 2004, Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression, Proc. Natl. Acad. Sci. USA, 101, 591, 10.1073/pnas.2535911100 · DOI · Paper page
- Buchanan, 2003, Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor, J. Biol. Chem., 278, 35451, 10.1074/jbc.M302474200 · DOI · Paper page
- Xiang, 2009, Induction of myeloid-derived suppressor cells by tumor exosomes, Int. J. Cancer, 124, 2621, 10.1002/ijc.24249 · DOI · Paper page
- Heusinkveld, 2011, M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells, J. Immunol., 187, 1157, 10.4049/jimmunol.1100889 · DOI · Paper page
- Chen, 2014, Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression, Breast Cancer Res., 16, 410, 10.1186/s13058-014-0410-1 · DOI
- Wculek, 2015, Neutrophils support lung colonization of metastasis-initiating breast cancer cells, Nature, 528, 413, 10.1038/nature16140 · DOI · Paper page
- Kuwata, 2013, Extracellular lipid metabolism influences the survival of ovarian cancer cells, Biochem. Biophys. Res. Commun., 439, 280, 10.1016/j.bbrc.2013.08.041 · doi:10.1016/j.bbrc.2013.08.041
- Visentin, 2006, Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages, Cancer Cell, 9, 225, 10.1016/j.ccr.2006.02.023 · DOI · Paper page
- Anelli, 2010, Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro, FASEB J., 24, 2727, 10.1096/fj.09-150540 · DOI
- Kanaporis, 2011, Gap junction permeability: Selectivity for anionic and cationic probes, Am. J. Physiol. Cell Physiol., 300, C600, 10.1152/ajpcell.00316.2010 · doi:10.1152/ajpcell.00316.2010
- Wu, 2019, Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application, J. Biomed. Sci., 26, 8, 10.1186/s12929-019-0497-x · DOI
- Tang, 2011, Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes, Med. Oncol., 28, 502, 10.1007/s12032-010-9492-5 · doi:10.1007/s12032-010-9492-5
- Alaga, 2017, Aberrant Cx43 Expression and Mislocalization in Metastatic Human Melanomas, J. Cancer, 8, 1123, 10.7150/jca.18569 · DOI
- Jensen, 2011, Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis, Endocr. Relat. Cancer, 18, 613, 10.1530/ERC-10-0289 · DOI
- Kong, 2016, All-trans retinoic acid enhances bystander effect of suicide gene therapy in the treatment of breast cancer, Oncol. Rep., 35, 1868, 10.3892/or.2015.4535 · DOI
- Heiniger, 2010, Second-generation substituted quinolines as anticancer drugs for breast cancer, Anticancer Res., 30, 3927
- Wang, 2018, The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability, Cancer Cell, 34, 823, 10.1016/j.ccell.2018.10.002 · DOI
- Yang, 2018, Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression, Cancer Res., 78, 3761, 10.1158/0008-5472.CAN-18-0040 · DOI
- Dang, 2016, Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer, Expert Rev. Anticancer Ther., 16, 13, 10.1586/14737140.2016.1123626 · DOI
- Sundar, 2015, Nivolumab in NSCLC: Latest evidence and clinical potential, Ther. Adv. Med. Oncol., 7, 85, 10.1177/1758834014567470 · DOI · Paper page
- Philips, 2015, Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies, Int. Immunol., 27, 39, 10.1093/intimm/dxu095 · DOI · Paper page
- Wang, 2016, A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer, Medicine (Baltimore), 95, e5539, 10.1097/MD.0000000000005539 · DOI
- Besse, 2013, Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer, Ann. Oncol., 24, 90, 10.1093/annonc/mds281 · DOI
- Sarkari, 2019, Abstract 5156: In vitro application of tumor-treating fields to suppress tunneling nanotubes in mesothelioma, Cancer Res., 79, 5156, 10.1158/1538-7445.AM2019-5156 · doi:10.1158/1538-7445.am2019-5156
- Sarkari, 2019, Tumor-Treating Fields (TTFields) Suppress Tunneling Nanotube Formation in Malignant Mesothelioma, Int. J. Radiat. Oncol. Biol. Phys., 105, E662, 10.1016/j.ijrobp.2019.06.1058 · DOI
- Desir, S., O’Hare, P., Vogel, R., Sperduto, W., Sarkari, A., Dickson, E., Wong, P., Nelson, A., Fong, Y., and Steer, C. (2018). Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer. Sci. Rep., 8. · DOI
- Desir, 2016, Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells, Oncotarget, 7, 43150, 10.18632/oncotarget.9504 · DOI
- Weil, 2017, Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas, Neuro Oncol., 19, 1316, 10.1093/neuonc/nox070 · DOI · Paper page
- Haderk, 2017, Tumor-derived exosomes modulate PD-L1 expression in monocytes, Sci. Immunol., 2, eaah5509, 10.1126/sciimmunol.aah5509 · DOI · Paper page
- Tian, 2019, Potential Role of Exosomes in Cancer Metastasis, Biomed Res. Int., 2019, 4649705, 10.1155/2019/4649705 · DOI
- Dong, 2012, Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma, World J. Gastroenterol., 18, 1806, 10.3748/wjg.v18.i15.1806 · DOI
- Richards, 2017, Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells, Oncogene, 36, 1770, 10.1038/onc.2016.353 · DOI · Paper page
- Marleau, 2012, Exosome removal as a therapeutic adjuvant in cancer, J. Transl. Med., 10, 134, 10.1186/1479-5876-10-134 · DOI · Paper page
- Tai, 2018, Exosomes in cancer development and clinical applications, Cancer Sci., 109, 2364, 10.1111/cas.13697 · DOI · Paper page
- Iero, 2008, Tumour-released exosomes and their implications in cancer immunity, Cell Death Differ., 15, 80, 10.1038/sj.cdd.4402237 · DOI · Paper page
- Rahbarghazi, 2019, Tumor-derived extracellular vesicles: Reliable tools for Cancer diagnosis and clinical applications, Cell Commun. Signal., 17, 73, 10.1186/s12964-019-0390-y · DOI · Paper page
- Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 · DOI · Paper page
- Rodon, 2015, First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma, Clin. Cancer Res., 21, 553, 10.1158/1078-0432.CCR-14-1380 · DOI · Paper page
- Kelley, 2019, A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma, Clin. Transl. Gastroenterol., 10, e00056, 10.14309/ctg.0000000000000056 · DOI · Paper page
- Herbertz, 2015, Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway, Drug Des. Dev. Ther., 9, 4479
- Fuji, 2018, Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: Clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation, Haematologica, 103, e211, 10.3324/haematol.2017.184564 · doi:10.3324/haematol.2017.184564
- Allison, 2017, Kidney cancer: CCR4: A new target for RCC, Nat. Rev. Nephrol., 13, 192, 10.1038/nrneph.2017.14 · doi:10.1038/nrneph.2017.14
- Massara, 2019, Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy, Front. Immunol., 10, 379, 10.3389/fimmu.2019.00379 · DOI · Paper page
- Shinriki, 2011, Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma, J. Pathol., 225, 142, 10.1002/path.2935 · DOI
- Jeannot, 2016, Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma, Onco Targets Ther., 9, 6843, 10.2147/OTT.S117743 · DOI
- Rock, 2007, Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma, Oncologist, 12, 107, 10.1634/theoncologist.12-1-107 · DOI · Paper page
- Chau, 2013, Vandetanib for the Treatment of Medullary Thyroid Cancer, Clin. Cancer Res., 19, 524, 10.1158/1078-0432.CCR-12-2353 · DOI
- Raouf, 2019, Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: A systematic literature review, Future Oncol., 15, 543, 10.2217/fon-2018-0480 · DOI
- Gardner, V., Madu, C., and Lu, Y. (2017). Anti-VEGF Therapy in Cancer: A Double-Edged Sword. Physiologic and Pathologic Angiogenesis. Signaling Mechanisms and Targeted Therapy, InTechOpen. · DOI
- Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5 · DOI · Paper page
- Pardee, 2014, A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies, Clin. Cancer Res., 20, 5255, 10.1158/1078-0432.CCR-14-1019 · DOI
- Lycan, T.W., Pardee, T.S., Petty, W.J., Bonomi, M., Alistar, A., Lamar, Z.S., Isom, S., Chan, M.D., Miller, A.A., and Ruiz, J. (2016). A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS ONE, 11. · DOI
- Kamisuki, 2009, A small molecule that blocks fat synthesis by inhibiting the activation of SREBP, Chem. Biol., 16, 882, 10.1016/j.chembiol.2009.07.007 · DOI · Paper page
- Stepulak, 2015, Comprehensive review on betulin as a potent anticancer agent, Biomed Res. Int., 2015, 584189
- Siqingaowa, 2017, Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation, Biochem. Biophys. Res. Commun., 488, 136, 10.1016/j.bbrc.2017.05.023 · DOI
- Cheng, 2018, SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy, Curr. Top. Med. Chem., 18, 484, 10.2174/1568026618666180523104541 · DOI
- Koundouros, 2020, Reprogramming of fatty acid metabolism in cancer, Br. J. Cancer, 122, 4, 10.1038/s41416-019-0650-z · DOI · Paper page
- Dean, 2016, Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, J. Clin. Oncol., 34, 2512, 10.1200/JCO.2016.34.15_suppl.2512 · DOI
- Kock, 2018, Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth, EBioMedicine, 32, 84, 10.1016/j.ebiom.2018.05.008 · DOI
- Britten, 2017, A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors, Clin. Cancer Res., 23, 4642, 10.1158/1078-0432.CCR-16-2363 · DOI · Paper page
- Eugenin, E. (2019). Role of cell-to-cell communication in cancer: New features, insights, and directions. Cancer Rep. · DOI
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Cancer associated-fibroblast-derived exosomes in cancer progression
Li, C., Teixeira, A. F., Zhu, H.-J., & ten Dijke, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01463-y · Cited by 336
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299
Self-citationFibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis
Curtis, M., Kenny, H. A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.007 · Cited by 290
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Metadata
- Authors
- Dominiak, A., Chełstowska, B., Olejarz, W., & Nowicka, G.
- Affiliations
- Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland
- Department of Internal Medicine and Hematology, Laboratory of Hematology and Flow Cytometry, Military Institute of Medicine, 04-140 Warsaw, Poland
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-05-14
- Volume
- 12
- Issue
- 5
- Pages
- 1232
- ISSN
- 2072-6694
- Cited by
- 188
- References
- 16
- Language
- en
- Funders
- Medical University of Warsaw (Profile of selected factors secreted by fibroblasts at various cancer stages)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. https://app.cochat.ai/papers/10.3390/cancers12051232
- The paper
- Dominiak, A., Chełstowska, B., Olejarz, W., & Nowicka, G. (2020). Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. Cancers. https://doi.org/10.3390/cancers12051232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.